Skip to main content

Diana Fernandes de Rafael

I possess a Master in Pharmaceutical Sciences (2010) granted by the Faculty of Pharmacy from the Lisbon University, and a PhD degree in Pharmaceutical Technology (2017) from the same University. During my PhD I had the opportunity to do research stays at Ludwig Maximillian University (LMU), Munich, Bellvitge Biomedical Research Institute (IDIBELL) and Vall D'Hebron Research Institute (VHIR), Barcelona. Actually, I am a post-doctoral researcher at Drug Delivery and Targeting Group, VHIR working in the field of nanotechnology-based drug delivery systems applied to several diseases.

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Diana Fernandes de Rafael

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

I possess a Master in Pharmaceutical Sciences (2010) granted by the Faculty of Pharmacy from the Lisbon University, and a PhD degree in Pharmaceutical Technology (2017) from the same University. During my PhD I had the opportunity to do research stays at Ludwig Maximillian University (LMU), Munich, Bellvitge Biomedical Research Institute (IDIBELL) and Vall D'Hebron Research Institute (VHIR), Barcelona. Actually, I am a post-doctoral researcher at Drug Delivery and Targeting Group, VHIR working in the field of nanotechnology-based drug delivery systems applied to several diseases.

Being a multidisciplinary scientist, during 10 years of research career I acquired expertise in different areas of knowledge such as Pharmaceutical Technology, Nanomedicine, Chemistry, Molecular Biology, Cancer Signalling Pathways, Preclinical Validation, etc. My board knowledge in the field of biomedical sciences granted by my training as pharmacist and my research experience, allowed me to have a comprehensive and integrative view of the different stages of drug development from the bench to the bedside. My career has been fully dedicated to the design, development, and preclinical validation of innovative delivery systems for a wide range of challenging diseases with a special attention to oncology.
My active participation at different international projects (12) and collaborations with a variety of research groups have resulted in the authorship of several publications in high impact peer-reviewed journals (35 publications, 15 as corresponding/first author, h-index 18). Also, she is co-inventor of two patents about delivery systems for gene delivery and the creation of cell penetrating peptides. Moreover, I am truly active in science dissemination both to share the knowhow with the pairs at international conferences, and also in citizenship dissemination actions. Additionally, due to her experience in the fields of Pharmaceutical Technology and Molecular Biology, I am giving classes at the Master of Molecular Biotechnology from the University of Barcelona. Most importantly, I was responsible for the supervision of the thesis of different pre-graduated, master and PhD students (14).

Projects

Terapia combinada mediante nuevos nanoconjugados terapéuticos contra Células Madre Tumorales en tumores de mamas triple negativos

IP: Simon Schwartz Navarro
Collaborators: Laura García Latorre, Joaquin Seras Franzoso, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael
Funding agency: Instituto de Salud Carlos III
Funding: 123420
Reference: PI17/02242
Duration: 01/01/2018 - 31/12/2020

(Nano) systems with active targeting to sensitize colorectal cancer stem cells to anti-tumoral treatment Target4Cancer

IP: Simon Schwartz Navarro
Collaborators: Laura García Latorre, Joaquin Seras Franzoso, Diana Fernandes de Rafael
Funding agency: Instituto de Salud Carlos III
Funding: 143385
Reference: AC15/00092
Duration: 01/01/2016 - 30/09/2019

Liberación dirigida de nanoconjugados de inhibidor de Alox5 contra células madre tumorales

IP: Simon Schwartz Navarro
Collaborators: Laura García Latorre, Diana Fernandes de Rafael
Funding agency: Instituto de Salud Carlos III
Funding: 171215
Reference: PI14/02079
Duration: 01/01/2015 - 31/12/2017

Related news

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Related professionals

Santos Ortega, Alba

Santos Ortega, Alba

Predoctoral researcher
Cardiovascular Diseases
Read more
Xavier Cañas Perea

Xavier Cañas Perea

Director/a d'Àrea
Clinical Research Development Directorate
Read more
Ruiz Esteve, Fernando

Ruiz Esteve, Fernando

Research technician
Neurovascular Diseases
Read more
Marcos Prieto, Susana

Marcos Prieto, Susana

Research technician
Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.